Insmed Incorporated reported its financial results for the third quarter ended September 30, 2026, with total company revenues reaching $524.4 Million. This performance was driven by BRINSUPRI revenues of $400.1 Million, representing 29% growth over the second quarter of 2026, an

Insmed Incorporated Reports Third-Quarter 2026 Revenues of $524.4 Million

(RTTNews) - Insmed Inc (INSM) revealed Loss for third quarter of -$100.32 million

Insmed Inc Q3 Loss Narrows 

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mercury General Corp. (Symbol: MCY), where a total of 2,961 contracts have traded so far, representing approximately 296,100 underlying shares.  That amounts to about 96.

Notable Tuesday Option Activity: MCY, INSM, REPL

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.66% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.87%.  December E-mini S&P futures (ESZ26 ) rose +0.67%, and December E-mini...

Stocks Settle Higher as Big Tech Rallies

The S&P 500 Index ($SPX ) (SPY ) is up by +0.44% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.63%.  December E-mini S&P futures (ESZ26 ) are up +0.41%, and December E-mini...

Stocks Mostly Higher as Crude Prices Fall

The S&P 500 Index ($SPX ) (SPY ) is up by +0.16% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.37%.  December E-mini S&P futures (ESZ26 ) are up +0.14%, and December E-mini...

Stocks Supported by M&A Activity and Lower Crude Oil Prices

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated News